Key Scientific Features & Chemical Profile of CJC 1295 + Ipamorelin (No DAC)
CJC 1295 + Ipamorelin (No DAC) combines a modified GHRH analogue with a selective ghrelin receptor secretagogue analogue for laboratory research involving pituitary signaling, GH-IGF-1 axis models, and receptor-pathway interaction studies.
Molecular Data
Property Value Name CJC-1295 (No DAC) + Ipamorelin Blend Classification Dual peptide research blend combining a GHRH analogue with a ghrelin receptor secretagogue analogue Components CJC-1295 (No DAC) and Ipamorelin, supplied as a 5mg / 5mg blended vial CJC-1295 Sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 Ipamorelin Sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 Molecular Formula CJC-1295 (No DAC): C165H269N47O46 / Ipamorelin: C38H49N9O5 Molecular Weight CJC-1295 (No DAC): ~3,357 Da; Ipamorelin: ~711 Da PubChem CID CJC-1295 (No DAC): 91971820; Ipamorelin: 9831659 CAS Number CJC-1295 (No DAC): 446262-90-4; Ipamorelin: 170851-70-4 Receptor Targets GHRH receptor signaling, GHS-R1a receptor signaling, GH-IGF-1 axis research, and pituitary secretagogue pathway models Physical Form Lyophilized powder supplied in sterile 5mg / 5mg research vials Solubility Soluble in sterile water or bacteriostatic water under controlled laboratory conditions Total Amount 10mg total blend amount Batch EP-250602-CI5
Purity & Quality Standards
SparkPeptide supplies CJC 1295 + Ipamorelin (No DAC) as a lyophilized research peptide with >=99% purity standards supported by lot-specific analytical documentation. The purity specification is intended to help research teams reduce variability from synthesis byproducts, degradation products, residual contaminants, and unrelated analytical noise.
Each lot is tied to a Certificate of Analysis so laboratories can match the received material to the corresponding identity, purity, and safety screening records. This traceability is especially important when CJC 1295 + Ipamorelin (No DAC) is being compared across experimental conditions, time points, or assay systems.
Analytical Verification
High-Performance Liquid Chromatography (HPLC): Reverse-phase HPLC is used to evaluate purity by separating the target CJC 1295 + Ipamorelin (No DAC) signal from synthesis-related impurities and degradation products. Chromatographic review helps confirm that the primary analytical peak represents the dominant component of the tested batch.
Mass Spectrometry (MS): Mass spectrometry confirms molecular identity by comparing the observed molecular mass with the expected value calculated from the reported molecular profile. This identity check helps verify that the material supplied matches the stated CJC 1295 + Ipamorelin (No DAC) specification.
Additional Safety Screening
Beyond core purity and identity testing, SparkPeptide uses additional safety screening to reduce contaminant-driven research artifacts. These screens are designed for laboratory quality control and batch transparency.
Screen What It Verifies Endotoxin Testing CJC 1295 + Ipamorelin (No DAC) batches are screened for bacterial endotoxins using LAL-based analytical methods where applicable to help reduce inflammatory assay interference in research models. Heavy Metals Screening Testing reviews lead, mercury, arsenic, cadmium, and related elemental contaminants that can enter peptide materials during synthesis, handling, or packaging. Sterility / Microbial Screening Microbial and sterility-oriented screening helps confirm the lyophilized research material is suitable for controlled laboratory workflows. Solubility Review Laboratory reconstitution behavior is reviewed against appropriate aqueous research solvents or buffers so researchers can prepare consistent working solutions.
Certificate of Analysis
The Certificate of Analysis documents the analytical results associated with the specific CJC 1295 + Ipamorelin (No DAC) lot supplied to researchers. It records purity testing, mass-based identity verification, and safety screening information such as endotoxin, heavy metals, and sterility or microbial review where applicable.
Researchers can use the COA for batch traceability, assay documentation, and internal quality review. Complete analytical reports are available through the SparkPeptide lab tests page or by request when additional batch documentation is needed.
Research Context
CJC-1295 (No DAC) is used in research models focused on GHRH receptor signaling, while Ipamorelin is studied in relation to GHS-R1a receptor activity. The blend allows laboratories to evaluate dual-pathway peptide signaling under controlled experimental conditions.
Because this blend contains two peptide components, lot-specific identity confirmation, purity analysis, endotoxin testing, heavy metals screening, and microbial review are important for reducing assay variability and component-specific uncertainty.
Research Use Only
For laboratory research use only. CJC 1295 + Ipamorelin (No DAC) is not intended for human consumption, veterinary use, clinical administration, diagnostic procedures, therapeutic use, or household application. The material is supplied exclusively for lawful laboratory research by qualified researchers and institutions.